Plasmodium gallinaceum: effects of various compounds on immunity of susceptible Aedes aegypti and refractory Culex pipiens pipiens.

R. Noblet,A. Weathersby

DOI: https://doi.org/10.1016/0014-4894(73)90101-X

IF: 2.132

1973-12-01

Experimental Parasitology

Abstract:

What problem does this paper attempt to address?

Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers

Tobias Brummer,Muthuraman Muthuraman,Falk Steffen,Timo Uphaus,Lena Minch,Maren Person,Frauke Zipp,Sergiu Groppa,Stefan Bittner,Vinzenz Fleischer

DOI: https://doi.org/10.1093/braincomms/fcac153

2022-07-08

Abstract:Disability in multiple sclerosis is generally classified by sensory and motor symptoms, yet cognitive impairment has been identified as a frequent manifestation already in the early disease stages. Imaging- and more recently blood-based biomarkers have become increasingly important for understanding cognitive decline associated with multiple sclerosis. Thus, we sought to determine the prognostic utility of serum neurofilament light chain levels alone and in combination with MRI markers by examining their ability to predict cognitive impairment in early multiple sclerosis. A comprehensive and detailed assessment of 152 early multiple sclerosis patients (Expanded Disability Status Scale: 1.3 ± 1.2, mean age: 33.0 ± 10.0 years) was performed, which included serum neurofilament light chain measurement, MRI markers (i.e. T2-hyperintense lesion volume and grey matter volume) acquisition and completion of a set of cognitive tests (Symbol Digits Modalities Test, Paced Auditory Serial Addition Test, Verbal Learning and Memory Test) and mood questionnaires (Hospital Anxiety and Depression scale, Fatigue Scale for Motor and Cognitive Functions). Support vector regression, a branch of unsupervised machine learning, was applied to test serum neurofilament light chain and combination models of biomarkers for the prediction of neuropsychological test performance. The support vector regression results were validated in a replication cohort of 101 early multiple sclerosis patients (Expanded Disability Status Scale: 1.1 ± 1.2, mean age: 34.4 ± 10.6 years). Higher serum neurofilament light chain levels were associated with worse Symbol Digits Modalities Test scores after adjusting for age, sex Expanded Disability Status Scale, disease duration and disease-modifying therapy (B = -0.561; SE = 0.192; P = 0.004; 95% CI = -0.940 to -0.182). Besides this association, serum neurofilament light chain levels were not linked to any other cognitive or mood measures (all P-values > 0.05). The tripartite combination of serum neurofilament light chain levels, lesion volume and grey matter volume showed a cross-validated accuracy of 88.7% (90.8% in the replication cohort) in predicting Symbol Digits Modalities Test performance in the support vector regression approach, and outperformed each single biomarker (accuracy range: 68.6-75.6% and 68.9-77.8% in the replication cohort), as well as the dual biomarker combinations (accuracy range: 71.8-82.3% and 72.6-85.6% in the replication cohort). Taken together, early neuro-axonal loss reflects worse information processing speed, the key deficit underlying cognitive dysfunction in multiple sclerosis. Our findings demonstrate that combining blood and imaging measures improves the accuracy of predicting cognitive impairment, highlighting the clinical utility of cross-modal biomarkers in multiple sclerosis.
Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study

Matteo Azzimonti,Paolo Preziosa,Elisabetta Pagani,Paola Valsasina,Nicolò Tedone,Carmen Vizzino,Maria A. Rocca,Massimo Filippi

DOI: https://doi.org/10.1007/s00415-023-11778-z

2023-05-18

Journal of Neurology

Abstract:BackgroundHeterogeneous processes may contribute to cognitive impairment in multiple sclerosis (MS).ObjectiveTo apply a longitudinal multiparametric MRI approach to identify mechanisms associated with cognitive worsening in MS patients.Methods3 T brain functional and structural MRI scans were acquired at baseline and after a median follow-up of 3.4 years in 35 MS patients and 22 healthy controls (HC). Associations between cognitive worsening (reliable change index score < − 1.25 at the Rao’s battery) and longitudinal changes in regional T2-hyperintense white matter (WM) lesions, diffusion tensor microstructural WM damage, gray matter (GM) atrophy and resting state (RS) functional connectivity (FC) were explored.ResultsAt follow-up, HC showed no clusters of significant microstructural WM damage progression, GM atrophy or changes in RS FC. At follow-up, 10 MS patients (29%) showed cognitive worsening. Compared to cognitively stable, cognitively worsened MS patients showed more severe GM atrophy of the right anterior cingulate cortex and bilateral supplementary motor area (p < 0.001). Cognitively worsened vs cognitively stable MS patients showed also decreased RS FC in the right hippocampus of the right working memory network and in the right insula of the default mode network. Increased RS FC in the left insula of the executive control network was found in the opposite comparison (p < 0.001). No significant regional accumulation of focal WM lesions nor microstructural WM abnormalities occurred in both patients’ groups.ConclusionsGM atrophy progression in cognitively relevant brain regions combined with functional impoverishment in networks involved in cognitive functions may represent the substrates underlying cognitive worsening in MS.

clinical neurology
Predicting clinical progression and cognitive decline in patients with relapsing-remitting multiple sclerosis: a 6-year follow-up study

Karolina Kania,Mikołaj A Pawlak,Maria Forycka,Monika Wiłkość-Dębczyńska,Sławomir Michalak,Agnieszka Łukaszewska,Aleksandra Wyciszkiewicz,Aleksandra Wypych,Zbigniew Serafin,Justyna Marcinkowska,Wojciech Kozubski,Alicja Kalinowska-Łyszczarz,Mikołaj A. Pawlak

DOI: https://doi.org/10.5603/pjnns.97714

2024-02-07

Neurologia i Neurochirurgia Polska

Abstract:INTRODUCTION: Cognitive impairment occurs from the earliest stages of multiple sclerosis (MS) and progresses over time. The introduction of disease modifying therapies (DMTs) has changed the prognosis for MS patients, offering a potential opportunity for improvement in the cognitive arena as well.MATERIAL AND METHODS: 41 patients with relapsing-remitting multiple sclerosis (MS) were recruited to the study. Thirty patients were available for final follow-up and were included in the analysis. Baseline (BL) brain MRI including volumetry and neuropsychological tests were performed. Blood samples were collected at BL and follow-up (FU) and were tested for: vascular endothelial growth factor (VEGF), soluble vascular cell adhesion molecule-1 (sVCAM1), soluble platelet-endothelial CAM-1 (sPECAM1), and soluble intercellular CAM-1 (sICAM-1). Patients were invited for a final neuropsychological follow-up after a median of 6 years. Disease activity (relapses, EDSS increase, new/active brain lesions on MRI) was analysed between BL and FU.RESULTS: The study group deteriorated in the Rey-Osterrieth Complex Figure (ROCF) test (p = 0.001), but improved significantly in three other tests, i.e. semantic fluency test (p = 0.013), California Verbal Learning Test (CVLT, p = 0.016), and Word Comprehension Test (WCT, p < 0.001). EDSS increase correlated negatively with semantic fluency and WCT scores (r = -0.579, p = 0.001 and r = -0.391, p = 0.033, respectively). Improvements in semantic fluency test and WCT correlated positively with baseline deep grey matter, grey matter, and cortical volumes (p < 0.05, r > 0). Higher EDSS on FU correlated significantly negatively with baseline left and right pallidum, right caudate, right putamen, right accumbens, and cortical volume (p < 0.05, r < 0). No significant relationship was found between the number of relapses and EDSS on FU or neuropsychological deteriorations. Improvements in WCT and CVLT correlated positively with baseline sPECAM1 and sVCAM1 results, respectively (r > 0, p < 0.05). Deterioration in ROCF test correlated significantly with higher levels of baseline VEGF and sVCAM1 (p < 0.05).CONCLUSIONS: Brain volume is an important predictor of future EDSS and cognitive functions outcome. MS patients have a potential for improving in neuropsychological tests over time. It remains to be established whether this is related to successful disease modification with immunotherapy. Baseline volumetric measures are stronger predictors of cognitive performance than relapse activity, which yet again highlights the importance of atrophy in MS prognosis.

clinical neurology
Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis

Samantha Noteboom,Moritz Seiler,Claudia Chien,Roshan P. Rane,Frederik Barkhof,Eva M. M. Strijbis,Friedemann Paul,Menno M. Schoonheim,Kerstin Ritter

DOI: https://doi.org/10.1007/s00415-024-12507-w

2024-06-24

Journal of Neurology

Abstract:Background Robust predictive models of clinical impairment and worsening in multiple sclerosis (MS) are needed to identify patients at risk and optimize treatment strategies. Objective To evaluate whether machine learning (ML) methods can classify clinical impairment and predict worsening in people with MS (pwMS) and, if so, which combination of clinical and magnetic resonance imaging (MRI) features and ML algorithm is optimal. Methods We used baseline clinical and structural MRI data from two MS cohorts (Berlin: n = 125, Amsterdam: n = 330) to evaluate the capability of five ML models in classifying clinical impairment at baseline and predicting future clinical worsening over a follow-up of 2 and 5 years. Clinical worsening was defined by increases in the Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk Test (T25FW), 9-Hole Peg Test (9HPT), or Symbol Digit Modalities Test (SDMT). Different combinations of clinical and volumetric MRI measures were systematically assessed in predicting clinical outcomes. ML models were evaluated using Monte Carlo cross-validation, area under the curve (AUC), and permutation testing to assess significance. Results The ML models significantly determined clinical impairment at baseline for the Amsterdam cohort, but did not reach significance for predicting clinical worsening over a follow-up of 2 and 5 years. High disability (EDSS ≥ 4) was best determined by a support vector machine (SVM) classifier using clinical and global MRI volumes (AUC = 0.83 ± 0.07, p = 0.015). Impaired cognition (SDMT Z -score ≤ −1.5) was best determined by a SVM using regional MRI volumes (thalamus, ventricles, lesions, and hippocampus), reaching an AUC of 0.73 ± 004 ( p = 0.008). Conclusion ML models could aid in classifying pwMS with clinical impairment and identify relevant biomarkers, but prediction of clinical worsening is an unmet need.

clinical neurology
Essential fatty acid deficiency depletes rat glomeruli of resident macrophages and inhibits angiotensin II-induced eicosanoid synthesis.

J. Lefkowith,G. Schreiner

DOI: https://doi.org/10.1172/JCI113187

IF: 19.456

1987-10-01

Journal of Clinical Investigation

Abstract:Essential fatty acid (EFA) deficiency exerts a beneficial effect on immune-mediated glomerulonephritis, preventing both the tissue injury and consequent mortality. Because both macrophages and eicosanoids are thought to play pathogenic roles in glomerulonephritis, and because macrophages play an important role in modulating arachidonate metabolism at sites of renal injury, the effects of EFA deficiency on the population of resident glomerular macrophages and on glomerular eicosanoid generation were examined. EFA deficiency led to a striking reduction in the number of resident glomerular macrophages and a corresponding reduction in the number of resident glomerular Ia+ cells. This phenomenon was not strain-specific, was not due to a decrease in circulating monocytes, was not a function of changes in cell surface labeling characteristics, and was not restricted to a specific subset of glomeruli. In addition, EFA deficiency affected other areas of the renal cortex: a comparable depletion of interstitial macrophages and Ia+ cells was also observed. In conjunction with the decrease in glomerular macrophages seen with the deficiency state, a marked decrease in both basal and angiotensin II-stimulated glomerular eicosanoid production was noted. In contrast to angiotensin II, platelet-activating factor-induced eicosanoid production was not significantly affected by the deficiency state. These changes in glomerular eicosanoid production could not be attributed to changes in glomerular cyclooxygenase or reacylation capacity. Dietary (n-6) fatty acid supplementation, but not (n-3) fatty acid supplementation, reversed both the decrease in glomerular macrophages and the diminished eicosanoid metabolism seen with the deficiency state. Understanding the mechanisms behind the changes in the glomerular microenvironment induced by EFA deficiency may provide a basis for elucidating the protective effect of dietary fatty acid manipulation on immune-mediated glomerulonephritis.
Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies

Nima Broomand Lomer,Kamal AmirAshjei Asalemi,Alia Saberi,Kasra Sarlak

DOI: https://doi.org/10.1371/journal.pone.0300415

IF: 3.7

2024-04-16

PLoS ONE

Abstract:Introduction Multiple Sclerosis (MS) is a chronic neurodegenerative disorder that affects the central nervous system (CNS) and results in progressive clinical disability and cognitive decline. Currently, there are no specific imaging parameters available for the prediction of longitudinal disability in MS patients. Magnetic resonance imaging (MRI) has linked imaging anomalies to clinical and cognitive deficits in MS. In this study, we aimed to evaluate the effectiveness of MRI in predicting disability, clinical progression, and cognitive decline in MS. Methods In this study, according to PRISMA guidelines, we comprehensively searched the Web of Science, PubMed, and Embase databases to identify pertinent articles that employed conventional MRI in the context of Relapsing-Remitting and progressive forms of MS. Following a rigorous screening process, studies that met the predefined inclusion criteria were selected for data extraction and evaluated for potential sources of bias. Results A total of 3028 records were retrieved from database searching. After a rigorous screening, 53 records met the criteria and were included in this study. Lesions and alterations in CNS structures like white matter, gray matter, corpus callosum, thalamus, and spinal cord, may be used to anticipate disability progression. Several prognostic factors associated with the progression of MS, including presence of cortical lesions, changes in gray matter volume, whole brain atrophy, the corpus callosum index, alterations in thalamic volume, and lesions or alterations in cross-sectional area of the spinal cord. For cognitive impairment in MS patients, reliable predictors include cortical gray matter volume, brain atrophy, lesion characteristics (T2-lesion load, temporal, frontal, and cerebellar lesions), white matter lesion volume, thalamic volume, and corpus callosum density. Conclusion This study indicates that MRI can be used to predict the cognitive decline, disability progression, and disease progression in MS patients over time.

multidisciplinary sciences
Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis

Leila Simani,Leila Molaeipour,Saeid Kian,Victoria M. Leavitt

DOI: https://doi.org/10.1007/s00415-024-12517-8

2024-06-20

Journal of Neurology

Abstract:Background While many studies have examined relationships of neuroimaging variables to cognitive measures in multiple sclerosis (MS), longitudinal studies are lacking. The relationship of cognitive changes to neuroradiological changes in MS is thus incompletely understood. The present study systematically reviews all studies reporting a relationship between MRI changes and cognitive changes after at least one year of follow-up. Method An extensive and methodical search of online databases was conducted to identify qualified studies until August 2023. Among various cognitive tests and magnetic resonance imaging (MRI) measures, Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), verbal fluency, T2 lesion volume (T2LV), white matter lesion volume (WML), and grey matter volume (GMV) qualified for inclusion in a meta-analysis investigating the association of cognitive changes to neuroradiological changes. Results We identified 35 studies that explored the link between MRI changes and changes in cognitive outcomes. Of these, twenty studies (57.14%) investigated the association between SDMT/PASAT and MRI metrics. Eleven studies (31.42%) focused on the relationship between MRI metrics and verbal learning and memory, while ten studies (28.57%) reported associations with visuospatial learning and memory. Furthermore, eight studies (22.85%) analyzed the correlation between verbal fluency and MRI measures. Only 5 were eligible for inclusion in the meta-analysis. The meta-analysis evaluated correlations between SDMT/PASAT and GMV ( r s = 0.67, 95% CI 0.44–0.91), and verbal fluency and T2LV ( r s = 0.35, 95% CI 0.09–0.60). Conclusion In this rigorously conducted systematic review, we found a significant association of cognitive changes, specifically SDMT/PASAT and verbal fluency, to changes in T2LV and atrophy in individuals with MS. Findings should be interpreted cautiously due to the limited amount of high-quality research, small sample sizes, and variability in study methodologies.

clinical neurology
Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers

Lele Xu,Xia Wu,Rui Li,Kewei Chen,Zhiying Long,Jiacai Zhang,Xiaojuan Guo,Li Yao

DOI: https://doi.org/10.3233/jad-151010

2016-01-01

Abstract:For patients with mild cognitive impairment (MCI), the likelihood of progression to probable Alzheimer's disease (AD) is important not only for individual patient care, but also for the identification of participants in clinical trial, so as to provide early interventions. Biomarkers based on various neuroimaging modalities could offer complementary information regarding different aspects of disease progression. The current study adopted a weighted multi-modality sparse representation-based classification method to combine data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, from three imaging modalities: Volumetric magnetic resonance imaging (MRI), fluorodeoxyglucose (FDG) positron emission tomography (PET), and florbetapir PET. We included 117 normal controls (NC) and 110 MCI patients, 27 of whom progressed to AD within 36 months (pMCI), while the remaining 83 remained stable (sMCI) over the same time period. Modality-specific biomarkers were identified to distinguish MCI from NC and to predict pMCI among MCI. These included the hippocampus, amygdala, middle temporal and inferior temporal regions for MRI, the posterior cingulum, precentral, and postcentral regions for FDG-PET, and the hippocampus, amygdala, and putamen for florbetapir PET. Results indicated that FDG-PET may be a more effective modality in discriminating MCI from NC and in predicting pMCI than florbetapir PET and MRI. Combining modality-specific sensitive biomarkers from the three modalities boosted the discrimination accuracy of MCI from NC (76.7%) and the prediction accuracy of pMCI (82.5%) when compared with the best single-modality results (73.6% for MCI and 75.6% for pMCI with FDG-PET).
Towards Multimodal Longitudinal Analysis for Predicting Cognitive Decline Using Neuroimaging Biomarkers, Cognitive Assessments, and Demographic Data

Rayan M Ashish,Jessica A. Turner

DOI: https://doi.org/10.1101/2024.11.18.624226

2024-11-19

Abstract:Understanding and predicting cognitive decline in Alzheimer's disease (AD) is crucial for timely intervention and management. While neuroimaging biomarkers and clinical assessments are valuable individually, their combined predictive power and interaction with demographic and cognitive variables remain underexplored. This study lays the groundwork for comprehensive longitudinal analyses by integrating neuroimaging markers and clinical data to predict cognitive changes over time. Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), feature-driven supervised machine learning techniques were applied to assess cognitive decline predictability. Results showed that while imaging biomarkers alone offered moderate predictive capabilities, including cognitive and demographic factors significantly improved model performance, with the Random-Forest model achieving near-perfect accuracy. The analysis highlighted the leading role of neuroimaging biomarkers as predictors, along with the importance of incorporating cognitive scores and demographic data to enhance predictability. Explainability analyses further revealed that clinical and demographic data could estimate brain imaging metrics, emphasizing the bidirectional nature of these relationships. This study underscores the need for integrating multi-dimensional data in future longitudinal research to capture time-dependent patterns in cognitive decline and guide the development of targeted intervention strategies. We also introduce and provide NeuroLAMA, an open and extensible data engineering and machine-learning system, to support the continued investigation by the community

Biology
Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis

Robert Zivadinov,Niels Bergsland,Dejan Jakimovski,Bianca Weinstock-Guttman,Lorena Lorefice,Menno M Schoonheim,Sarah A Morrow,Mary Ann Picone,Gabriel Pardo,Myassar Zarif,Mark Gudesblatt,Jacqueline A Nicholas,Andrew Smith,Samuel Hunter,Stephen Newman,Mahmoud A AbdelRazek,Ina Hoti,Jon Riolo,Diego Silva,Tom A Fuchs,Michael G Dwyer,Ralph Hb Benedict

DOI: https://doi.org/10.1016/j.nicl.2024.103609

Abstract:Background: Prior research has established a link between thalamic pathology and cognitive impairment (CI) in people with multiple sclerosis (pwMS). However, the translation of these findings to pwMS in everyday clinical settings has been insufficient. Objective: To assess which global and/or thalamic imaging biomarkers can be used to identify pwMS at risk for CI and cognitive worsening (CW) in a real-world setting. Methods: This was an international, multi-center (11 centers), longitudinal, retrospective, real-word study of people with relapsing-remitting MS (pwRRMS). Brain MRI exams acquired at baseline and follow-up were collected. Cognitive status was evaluated using the Symbol Digit Modalities Test (SDMT). Thalamic volume (TV) measurement was performed on T2-FLAIR, as well as on T1-WI, when available. Thalamic dysconnectivity, T2-lesion volume (T2-LV), and volumes of gray matter (GM), whole brain (WB) and lateral ventricles (LVV) were also assessed. Results: 332 pwMS were followed for an average of 2.8 years. At baseline, T2-LV, LVV, TV and thalamic dysconnectivity on T2-FLAIR (p < 0.016), and WB, GM and TV volumes on T1-WI (p < 0.039) were significantly worse in 90 (27.1 %) CI vs. 242 (62.9 %) non-CI pwRRMS. Greater SDMT decline over the follow-up was associated with lower baseline TV on T2-FLAIR (standardized β = 0.203, p = 0.002) and greater thalamic dysconnectivity (standardized β = -0.14, p = 0.028) in a linear regression model. Conclusions: PwRRMS with thalamic atrophy and worse thalamic dysconnectivity present more frequently with CI and experience greater CW over mid-term follow-up in a real-world setting.
Multivariate MR Biomarkers Better Predict Cognitive Dysfunction in Mouse Models of Alzheimers Disease

Alexandra Badea,Natalie A Delpratt,RJ Anderson,Russell Dibb,Yi Qi,Hongjiang Wei,Chunlei Liu,William C Wetsel,Brian B Avants,Carol Colton

DOI: https://doi.org/10.48550/arXiv.1812.11001

2018-12-28

Abstract:To understand multifactorial conditions such as Alzheimers disease (AD) we need brain signatures that predict the impact of multiple pathologies and their interactions. To help uncover the relationships between brain circuits and cognitive markers we have used mouse models that represent, at least in part, the complex interactions altered in AD. In particular, we aimed to understand the relationship between vulnerable brain circuits and memory deficits measured in the Morris water maze, and we tested several predictive modeling approaches. We used in vivo manganese enhanced MRI voxel based analyses to reveal regional differences in volume (morphometry), signal intensity (activity), and magnetic susceptibility (iron deposition, demyelination). These regions included the hippocampus, olfactory areas, entorhinal cortex and cerebellum. The image based properties of these regions were used to predict spatial memory. We next used eigenanatomy, which reduces dimensionality to produce sets of regions that explain the variance in the data. For each imaging marker, eigenanatomy revealed networks underpinning a range of cognitive functions including memory, motor function, and associative learning. Finally, the integration of multivariate markers in a supervised sparse canonical correlation approach outperformed single predictor models and had significant correlates to spatial memory. Among a priori selected regions, the fornix also provided good predictors, raising the possibility of investigating how disease propagation within brain networks leads to cognitive deterioration. Our results support that modeling approaches integrating multivariate imaging markers provide sensitive predictors of AD-like behaviors. Such strategies for mapping brain circuits responsible for behaviors may help in the future predict disease progression, or response to interventions.

Quantitative Methods,Neurons and Cognition
Exploring the neuromagnetic signatures of cognitive decline from mild cognitive impairment to Alzheimer's disease dementia

Sinead Gaubert,Pilar Garces,Jörg Hipp,Ricardo Bruña,Maria Eugenia Lopéz,Fernando Maestu,Delshad Vaghari,Richard Henson,Claire Paquet,Denis Engemann

DOI: https://doi.org/10.1101/2024.07.06.24310016

2024-07-07

Abstract:Introduction: Alzheimer's disease (AD) is the most common cause of dementia. Non-invasive, affordable, and largely available biomarkers that are able to identify patients at a prodromal stage of AD are becoming essential, especially in the context of new disease-modifying therapies. Mild cognitive impairment (MCI) is a critical stage preceding dementia, but not all MCI patients will progress to AD. This study explores the potential of non-invasive magnetoencephalography (MEG) to predict future cognitive decline from MCI to AD dementia. Methods: We analyzed resting state MEG data from the BioFIND dataset including 117 MCI patients, of whom 64 progressed to AD dementia (AD progression) while 53 remained stable (stable MCI) using multivariate spectral analyses. The patients were followed-up between 2009 and 2018. Receiver operating characteristic curves obtained via logistic regression models were used to quantify separation of patients progressing to AD dementia from stable MCI. Results: MEG beta power, particularly over parieto-occipital magnetometers, was significantly reduced in the AD progression group compared to stable MCI, indicative of future cognitive decline. Logistic regression models showed that MEG beta power outperformed conventional metrics like the Mini Mental Status Examination (MMSE) score and structural brain measures in predicting progression to AD dementia (AUC 0.81 vs 0.71 and AUC 0.81 vs 0.75, respectively). The combination of age, education, MMSE, MEG beta power and Hippocampal volume/Total grey matter ratio achieved a 0.83 AUC, 78% sensitivity and 76% specificity. Spectral covariance matrices analyzed with Riemannian methods exhibited significant differences between groups across a wider range of frequencies than spectral power. Discussion: These findings highlight the potential of spectral power and covariance as robust non-invasive electrophysiological biomarkers to predict MCI progression that complement other diagnostic measures, including cognitive scores, structural magnetic resonance imaging (MRI) and biological biomarkers.

Neurology
Prediction of cognitive decline in Parkinson's disease based on MRI radiomics and clinical features: A multicenter study

Yongjie Jian,Jiaxuan Peng,Wei Wang,Tao Hu,Jing Wang,Hui Shi,Xiaoyong Li,Jingfang Chen,Yuyun Xu,Yuan Shao,Qiaowei Song,Zhenyu Shu

DOI: https://doi.org/10.1111/cns.14789

2024-06-25

CNS Neuroscience & Therapeutics

Abstract:The multimodal model based on MRI radiomics combined with clinical features, may serve as good predictors of cognitive decline in Parkinson's disease. Objective To develop and validate a multimodal combinatorial model based on whole‐brain magnetic resonance imaging (MRI) radiomic features for predicting cognitive decline in patients with Parkinson's disease (PD). Methods This study included a total of 222 PD patients with normal baseline cognition, of whom 68 had cognitive impairment during a 4‐year follow‐up period. All patients underwent MRI scans, and radiomic features were extracted from the whole‐brain MRI images of the training set, and dimensionality reduction was performed to construct a radiomics model. Subsequently, Screening predictive factors for cognitive decline from clinical features and then combining those with a radiomics model to construct a multimodal combinatorial model for predicting cognitive decline in PD patients. Evaluate the performance of the comprehensive model using the receiver‐operating characteristic curve, confusion matrix, F1 score, and survival curve. In addition, the quantitative characteristics of diffusion tensor imaging (DTI) from corpus callosum were selected from 52 PD patients to further validate the clinical efficacy of the model. Results The multimodal combinatorial model has good classification performance, with areas under the curve of 0.842, 0.829, and 0.860 in the training, test, and validation sets, respectively. Significant differences were observed in the number of cognitive decline PD patients and corpus callosum‐related DTI parameters between the low‐risk and high‐risk groups distinguished by the model (p

pharmacology & pharmacy,neurosciences
Detection of cognitive deficits years prior to clinical diagnosis across neurological conditions

Xin You Tai,Sofia Toniolo,David Llewellyn,Cornelia Van Duijn,Masud Husain,Sanjay G Manohar

DOI: https://doi.org/10.1101/2024.07.10.24310213

2024-07-10

Abstract:Importance: Understanding the cognitive trajectory of a neurological disease can provide important insight on underlying mechanisms and disease progression. Cognitive impairment is now well established as beginning many years before the diagnosis of Alzheimer's disease, but pre-diagnostic profiles are unclear for other neurological conditions that may be associated with cognitive impairment. Objective: Compare pre-diagnostic and post-diagnostic cognition and global brain volume in ischaemic stroke, focal epilepsy, Parkinson's disease, multiple sclerosis, motor neurone disease (amyotrophic lateral sclerosis) and migraine using time-to-diagnosis and time-from-diagnosis data in relation to time of assessment. Design: Analysis the prospective UK Biobank cohort with study baseline assessment performed between 2006-2010 and participants followed until 2021. Setting: Multicenter, population-based study. Participants: Sample of 497,252 participants, aged between 38 and 72 years, at baseline with an imaging sub-sample of 42,468 participants. Exposure: Participants with each neurological condition were compared to a healthy control group. Main outcomes and measures: A continuous measure of executive function and magnetic resonance imaging brain measures of total grey matter and hippocampal volume. Results: Of the 497,252 participants (226,206 [45.5%] men, mean [SD] age, 57.5[8.1] years), 12,755 had ischaemic stroke, 6,758 had a diagnosis of focal epilepsy, 3,315 had Parkinson's disease, 2,315 had multiple sclerosis, 559 had motor neurone disease and 18,254 had migraine either at study baseline or diagnosed during the follow-up period. Apart from motor neurone disease, all conditions had lower pre-diagnosis executive function compared to controls (assessment performed median 7.4 years before diagnosis). Participants with focal epilepsy and multiple sclerosis showed a gradual worsening in executive function up to 15 years prior to diagnosis, while ischaemic stroke was characterised by a modest decline for a few years followed by a substantial reduction at the time of diagnosis. By contrast, participants with migraine showed improved post-diagnosis cognitive scores. Pre-diagnosis MRI grey matter volume was lower than controls for stroke, Parkinson's disease and multiple sclerosis (scans performed median 1.7 years before diagnosis), while other conditions had lower volumes post-diagnosis. Conclusion: These cognitive trajectory models reveal disease-specific temporal patterns, including a long cognitive prodrome associated with focal epilepsy and multiple sclerosis. The findings may help to prioritise risk management of individual diseases and inform clinical decision-making.

Neurology
Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis

X Lin,C R Tench,P S Morgan,C S Constantinescu

DOI: https://doi.org/10.1136/jnnp.2006.112177

2008-04-01

Abstract:BACKGROUND: Cognitive impairment is one of the frequent and early findings in multiple sclerosis (MS).OBJECTIVE: To determine the relation between cognitive abnormalities and the extent of macroscopic and microscopic tissue damage in the corpus callosum (CC), revealed by conventional magnetic resonance imaging (MRI), magnetisation transfer imaging (MTI) and diffusion tensor imaging (DTI).METHODS: Conventional dual-echo, DTI and MTI of the brain were obtained from 36 patients with relapsing remitting (RR) MS, and 13 age and gender matched normal controls. Voxels from CC were identified using a tractography based algorithm. Mean apparent diffusion coefficient (ADC(av)) and MT ratio were measured for the CC as defined by tractography. Corpus callosum area (CCA) was measured using edge detection on the mid-sagittal slice on high resolution MRI images. The Expanded Disability Status Scale (EDSS) and Paced Auditory Serial Addition Test (PASAT) were scored.RESULTS: Nine patients (25%) were found to be cognitively impaired. The CCA was not significantly different in the whole cohort of patients from controls (608.2 (428.6-713.0) mm(2) vs 674.2 (585.8-754.4) mm(2), p = 0.1), but was smaller in cognitively impaired than unimpaired group (417 (290-634) mm(2) vs 652 (511-718) mm(2), p = 0.04). The mean MT ratio of CC in patients was lower than in controls (0.41 (0.39-0.042) vs 0.43 (0.42-0.43), p<0.001). The ADC(av) in the CC in patients was higher than in controls (0.94 (0.89-0.99) vs 0.87 (0.85-0.89), p<0.001). PASAT was correlated with mean MT ratio (r = 0.47, p = 0.0046), ADC(av) (r = -0.53, p = 0.0012), CCA (r = 0.42, p = 0.01) and total T(2) lesion load (r = -0.4, p = 0.017), but not with T(2) lesion load within the CC (r = -0.24, p = 0.16), disease duration (r = -0.2, p = 0.24) or EDSS (r = -0.27, p = 0.12).CONCLUSIONS: ADC(av), MTR and atrophy measures in the CC may offer a sensitive method detecting subtle macroscopic and microscopic changes associated with cognitive impairment in MS.

surgery,psychiatry,clinical neurology
Prognostic value of single-subject grey matter networks in early multiple sclerosis

Vinzenz Fleischer,Gabriel Gonzalez-Escamilla,Deborah Pareto,Alex Rovira,Jaume Sastre-Garriga,Piotr Sowa,Einar A Høgestøl,Hanne F Harbo,Barbara Bellenberg,Carsten Lukas,Serena Ruggieri,Claudio Gasperini,Tomas Uher,Manuela Vaneckova,Stefan Bittner,Ahmed E Othman,Sara Collorone,Ahmed T Toosy,Sven G Meuth,Frauke Zipp,Frederik Barkhof,Olga Ciccarelli,Sergiu Groppa

DOI: https://doi.org/10.1093/brain/awad288

IF: 14.5

2024-01-04

Brain

Abstract:The identification of prognostic markers in early multiple sclerosis (MS) is challenging and requires reliable measures that robustly predict future disease trajectories. Ideally, such measures should make inferences at the individual level to inform clinical decisions. This study investigated the prognostic value of longitudinal structural networks to predict 5-year Expanded Disability Status Scale (EDSS) progression in patients with relapsing-remitting MS (RRMS). We hypothesized that network measures, derived from MRI, outperform conventional MRI measurements at identifying patients at risk of developing disability progression. This longitudinal, multicentre study within the Magnetic Resonance Imaging in MS (MAGNIMS) network included 406 patients with RRMS (mean age = 35.7 ± 9.1 years) followed up for 5 years (mean follow-up = 5.0 ± 0.6 years). EDSS was determined to track disability accumulation. A group of 153 healthy subjects (mean age = 35.0 ± 10.1 years) with longitudinal MRI served as controls. All subjects underwent MRI at baseline and again 1 year after baseline. Grey matter atrophy over 1 year and white matter lesion load were determined. A single-subject brain network was reconstructed from T1-weighted scans based on grey matter atrophy measures derived from a statistical parameter mapping-based segmentation pipeline. Key topological measures, including network degree, global efficiency and transitivity, were calculated at single-subject level to quantify network properties related to EDSS progression. Areas under receiver operator characteristic (ROC) curves were constructed for grey matter atrophy and white matter lesion load, and the network measures and comparisons between ROC curves were conducted. The applied network analyses differentiated patients with RRMS who experience EDSS progression over 5 years through lower values for network degree [H(2) = 30.0, P < 0.001] and global efficiency [H(2) = 31.3, P < 0.001] from healthy controls but also from patients without progression. For transitivity, the comparisons showed no difference between the groups [H(2) = 1.5, P = 0.474]. Most notably, changes in network degree and global efficiency were detected independent of disease activity in the first year. The described network reorganization in patients experiencing EDSS progression was evident in the absence of grey matter atrophy. Network degree and global efficiency measurements demonstrated superiority of network measures in the ROC analyses over grey matter atrophy and white matter lesion load in predicting EDSS worsening (all P-values < 0.05). Our findings provide evidence that grey matter network reorganization over 1 year discloses relevant information about subsequent clinical worsening in RRMS. Early grey matter restructuring towards lower network efficiency predicts disability accumulation and outperforms conventional MRI predictors.
Improved Prediction of Imminent Progression to Clinically Significant Memory Decline Using Surface Multivariate Morphometry Statistics and Sparse Coding

Cynthia M. Stonnington,Jianfeng Wu,Jie Zhang,Jie Shi,Robert J. Bauer,Vivek Devadas,Yi Su,Dona E. C. Locke,Eric M. Reiman,Richard J. Caselli,Kewei Chen,Yalin Wang

DOI: https://doi.org/10.3233/jad-200821

2021-01-01

Abstract:Background: Besides their other roles, brain imaging and other biomarkers of Alzheimer’s disease (AD) have the potential to inform a cognitively unimpaired (CU) person’s likelihood of progression to mild cognitive impairment (MCI) and benefit subject selection when evaluating promising prevention therapies. We previously described that among baseline FDG-PET and MRI measures known to be preferentially affected in the preclinical and clinical stages of AD, hippocampal volume was the best predictor of incident MCI within 2 years (79%sensitivity/78%specificity), using standard automated MRI volumetric algorithmic programs, binary logistic regression, and leave-one-out procedures. Objective: To improve the same prediction by using different hippocampal features and machine learning methods, cross-validated via two independent and prospective cohorts (Arizona and ADNI). Methods: Patch-based sparse coding algorithms were applied to hippocampal surface features of baseline TI-MRIs from 78 CU adults who subsequently progressed to amnestic MCI in approximately 2 years (“progressors”) and 80 matched adults who remained CU for at least 4 years (“nonprogressors”). Nonprogressors and progressors were matched for age, sex, education, and apolipoprotein E4 allele dose. We did not include amyloid or tau biomarkers in defining MCI. Results: We achieved 92%prediction accuracy in the Arizona cohort, 92%prediction accuracy in the ADNI cohort, and 90%prediction accuracy when combining the two demographically distinct cohorts, as compared to 79%(Arizona) and 72%(ADNI) prediction accuracy using hippocampal volume. Conclusion: Surface multivariate morphometry and sparse coding, applied to individual MRIs, may accurately predict imminent progression to MCI even in the absence of other AD biomarkers.
Multimodality Neuroimaging in Mild Cognitive Impairment: A Cross-sectional Comparison Study

R Sheelakumari,Sankara P Sarma,Chandrasekharan Kesavadas,Bejoy Thomas,Deepak Sasi,Lekha V Sarath,Sunitha Justus,Mridula Mathew,Ramshekhar N Menon

DOI: https://doi.org/10.4103/aian.AIAN_379_17

Abstract:Background and purpose: Mild cognitive impairment (MCI) is a focus of considerable research. The present study aimed to test the utility of a logistic regression-derived classifier, combining specific quantitative multimodal magnetic resonance imaging (MRI) data for the early objective phenotyping of MCI in the clinic, over structural MRI data. Methods: Thirty-three participants with cognitively stable amnestic MCI; 15 MCI converters to early Alzheimer's disease (AD; diseased controls) and 20 healthy controls underwent high-resolution T1-weighted volumetric MRI, diffusion tensor imaging (DTI), and proton magnetic resonance spectroscopy (1H MR spectroscopy). The regional volumes were obtained from T1-weighted MRI. The fractional anisotropy and mean diffusivity maps were derived from DTI over multiple white matter regions. The 1H MRS voxels were placed over posterior cingulate gyri, and N-acetyl aspartate (NAA)/creatine (Cr), choline (Cho)/Cr, myoinositol (mI/Cr), and NAA/mI ratios were obtained. A multimodal classifier comprising MR volumetry, DTI, and MRS was prepared. A cutoff point was arrived based on receiver operator characteristics analysis. Results were considered significant, if P < 0.05. Results: The most sensitive individual marker to discriminate MCI from controls was DTI (90.9%), with a specificity of 50%. For classifying MCI from AD, the best individual modality was DTI (72.7%), with a high specificity of 87.9%. The multimodal classifier approach for MCI control classification achieved an area under curve (AUC) (AUC = 0.89; P < 0.001), with 93.9% sensitivity and 70% specificity. The combined classifier for MCI-AD achieved a highest AUC (AUC = 0.93; P < 0.001), with 93% sensitivity and 85.6% specificity. Conclusions: The combined method of gray matter atrophy, white matter tract changes, and metabolite variation achieved a better performance at classifying MCI compared to the application of individual MRI biomarkers.
The evolving contribution of MRI measures towards the prediction of secondary progressive multiple sclerosis

Piriyankan Ananthavarathan,Nitin Sahi,Karen Chung,Lukas Haider,Ferran Prados,S Anand Trip,Olga Ciccarelli,Frederik Barkhof,Carmen Tur,Declan T Chard

DOI: https://doi.org/10.1136/jnnp-2024-333917

2024-07-22

Abstract:Background In multiple sclerosis (MS), both lesion accrual and brain atrophy predict clinical outcomes. However, it is unclear whether these prognostic features are equally relevant throughout the course of MS. Among 103 participants recruited following a clinically isolated syndrome (CIS) and followed up over 30 years, we explored (1) whether white matter lesions were prognostically more relevant earlier and brain atrophy later in the disease course towards development of secondary progressive (SP) disease; (2) if so, when the balance in prognostic contribution shifts and (3) whether optimised prognostic models predicting SP disease should include different features dependent on disease duration. Methods Binary logistic regression models were built using age, gender, brain lesion counts and locations, and linear atrophy measures (third ventricular width and medullary width) at each time point up to 20 years, using either single time point data alone or adjusted for baseline measures. Results By 30 years, 27 participants remained CIS while 60 had MS (26 SPMS and 16 MS-related death). Lesions counts were prognostically significant from baseline and at all later time points while linear atrophy measure models reached significance from 5 years. When adjusted for baseline, in combined MRI models including lesion count and linear atrophy measures, only lesion counts were significant predictors. In combined models including relapse measures, Expanded Disability Status Scale scores and MRI measures, only infratentorial lesions were significant predictors throughout. Conclusions While SPMS progression is associated with brain atrophy, in predictive models only infratentorial lesions were consistently prognostically significant.

surgery,psychiatry,clinical neurology
Analysis and visualization of the effect of multiple sclerosis on biological brain age

Catharina J. A. Romme,Emma A. M. Stanley,Pauline Mouches,Matthias Wilms,G. Bruce Pike,Luanne M. Metz,Nils D. Forkert

DOI: https://doi.org/10.3389/fneur.2024.1423485

IF: 3.4

2024-10-11

Frontiers in Neurology

Abstract:Introduction: The rate of neurodegeneration in multiple sclerosis (MS) is an important biomarker for disease progression but can be challenging to quantify. The brain age gap, which quantifies the difference between a patient's chronological and their estimated biological brain age, might be a valuable biomarker of neurodegeneration in patients with MS. Thus, the aim of this study was to investigate the value of an image-based prediction of the brain age gap using a deep learning model and compare brain age gap values between healthy individuals and patients with MS. Methods: A multi-center dataset consisting of 5,294 T1-weighted magnetic resonance images of the brain from healthy individuals aged between 19 and 89 years was used to train a convolutional neural network (CNN) for biological brain age prediction. The trained model was then used to calculate the brain age gap in 195 patients with relapsing remitting MS (20–60 years). Additionally, saliency maps were generated for healthy subjects and patients with MS to identify brain regions that were deemed important for the brain age prediction task by the CNN. Results: Overall, the application of the CNN revealed accelerated brain aging with a larger brain age gap for patients with MS with a mean of 6.98 ± 7.18 years in comparison to healthy test set subjects (0.23 ± 4.64 years). The brain age gap for MS patients was weakly to moderately correlated with age at disease onset (ρ = −0.299, p < 0.0001), EDSS score (ρ = 0.206, p = 0.004), disease duration (ρ = 0.162, p = 0.024), lesion volume (ρ = 0.630, p < 0.0001), and brain parenchymal fraction (ρ = −0.718, p < 0.0001). The saliency maps indicated significant differences in the lateral ventricle ( p < 0.0001), insula ( p < 0.0001), third ventricle ( p < 0.0001), and fourth ventricle ( p = 0.0001) in the right hemisphere. In the left hemisphere, the inferior lateral ventricle ( p < 0.0001) and the third ventricle ( p < 0.0001) showed significant differences. Furthermore, the Dice similarity coefficient showed the highest overlap of salient regions between the MS patients and the oldest healthy subjects, indicating that neurodegeneration is accelerated in this patient cohort. Discussion: In conclusion, the results of this study show that the brain age gap is a valuable surrogate biomarker to measure disease progression in patients with multiple sclerosis.

neurosciences,clinical neurology

Plasmodium gallinaceum: effects of various compounds on immunity of susceptible Aedes aegypti and refractory Culex pipiens pipiens.

Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers

Functional and structural brain MRI changes associated with cognitive worsening in multiple sclerosis: a 3-year longitudinal study

Predicting clinical progression and cognitive decline in patients with relapsing-remitting multiple sclerosis: a 6-year follow-up study

Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis

Essential fatty acid deficiency depletes rat glomeruli of resident macrophages and inhibits angiotensin II-induced eicosanoid synthesis.

Predictors of multiple sclerosis progression: A systematic review of conventional magnetic resonance imaging studies

Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis

Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers

Towards Multimodal Longitudinal Analysis for Predicting Cognitive Decline Using Neuroimaging Biomarkers, Cognitive Assessments, and Demographic Data

Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis

Multivariate MR Biomarkers Better Predict Cognitive Dysfunction in Mouse Models of Alzheimers Disease

Exploring the neuromagnetic signatures of cognitive decline from mild cognitive impairment to Alzheimer's disease dementia

Prediction of cognitive decline in Parkinson's disease based on MRI radiomics and clinical features: A multicenter study

Detection of cognitive deficits years prior to clinical diagnosis across neurological conditions

Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis

Prognostic value of single-subject grey matter networks in early multiple sclerosis

Improved Prediction of Imminent Progression to Clinically Significant Memory Decline Using Surface Multivariate Morphometry Statistics and Sparse Coding

Multimodality Neuroimaging in Mild Cognitive Impairment: A Cross-sectional Comparison Study

The evolving contribution of MRI measures towards the prediction of secondary progressive multiple sclerosis

Analysis and visualization of the effect of multiple sclerosis on biological brain age